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routine screening for asymptomatic carotid artery stenosis.
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Reply
We appreciate the opportunity to respond to the letter
of Dr Norris et al. We would, however, like to clarify some
of their concerns. The interest in carotid angioplasty and
the impetus for a randomized trial is surprisingly wide-
spread. Thus, we have concerns about the issue of carotid
angioplasty and stenting. Dr Norris did not completely
state our conclusions that "we do not support further clin-
ical investigation in a randomized fashion."l We do agree
that further clinical investigation may be necessary, but
there is no uncertainty in our minds about the differences
in these two therapeutic methods. When considering the
"equipoise of clinical research," the surgeons at the
University ofAlabama at Birmingham do not have "a state
of genuine uncertainty... regarding the comparative thera-
peutic merits" of these two forms of therapy.2 Therefore,
we ask why these authors would consider a trial if they
agree that percutaneous transluminal angioplasty with
stenting is not an acceptable alternative to carotid
endarterectomy?
I also would like to further clarify other points in this let-
ter. All ofthe patients who were symptomatic in the Alabama
series were not "rejected for surgery." Approximately 40% to
45% of the patients were referred by surgeons, most of
whom work outside of our institution. Less than 10% of the
patients who underwent treatment with carotid angioplasty
and stenting in this series were referred by these authors. Of
note, from our previous reports, more patients were refused
for angioplasty and stenting and ultimately underwent surgi-
cal therapy than crossover from the surgical to medical side.
We wholeheartedly agree that this new procedure
should be evaluated on a "scientific footing" as Dr Norris
comments. However, to state that the only valid scientific
evaluation is done in a randomized prospective clinical
trial is foolish and unwise. Our scientific knowledge is not
limited to randomized prospective trials, as some would
have us believe. If a randomized prospective trial was
undertaken with 600 patients, please consider the follow-
ing outcomes: with the stroke rate of these authors of
18%, 300 randomized patients would have 54 strokes. If
one considers the recently reported 2.67% stroke rate of
the largest clinical report of carotid endarterectomy in
patients who were symptomatic,3 then there would be
eight strokes in a randomized group of 300 patients. By
that calculation, 46 people are inappropriately exposed to
stroke because of our scientific community's inability to
make an appropriate judgement about a new therapy with-
out the benefit of a randomized clinical trial. We consider
that an inappropriate risk.
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We would ask, instead, that carotid physicians
throughout the world not be blinded by the fallacy that
clinical information is only obtained in randomized clini-
cal trials.
William D. Jordan, Jr, MD
David C. Voellinger, MD
Winfield S. Fisher, MD
Holt A. McDowell, MD
Department of Surgery and Biostatistics
University ofAlabama at Birmingham
Birmingham, Ala
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Regarding "Aortoiliac stent deployment versus
surgical reconstruction: analysis of outcome and cost"
To the Editors:
I read with interest the article by Jeffrey L. Ballard and
colleagues (J Vasc Surg 1998;28:94-103), and it was clear
to me that the data presented contained significant flaws.
Besides patient selection bias, the patency rate and cost
analysis was skewed to heavily favor surgery over stent
deployment. It is notable that although one half of the
cases were performed by interventional radiologists, none
were included in the author list.
This consecutive, nonrandomized study resulted in
the surgery group having a significantly higher percentage
ofpatients with better runoff vessels. For instance, 70% of
the surgery group had a patent superficial femoral artery,
with 54% with three-vessel tibial runoff, as compared with
56% and 38%, respectively, for the stent group. The
surgery group had a one-vessel tibial runoff in only 8% of
the cases as compared with 30% for the stent group. The
disparity heavily favors the surgery group. To quote the
authors of the article, "Compromised infrainguinal runoff
has been noted to have an adverse affect on long-term
aortofemoral bypass graft patency, as well as on stented
iliac artery patency." This fact may have contributed to the
higher patency rates reported for the surgery group. In
addition, in their calculations, the authors excluded
patients with category 1 aortoiliac disease who underwent
treatment with stent deployment. These patients tend to
have high long-term patency rates, and, by this exclusion,
the patency rates again heavily favor the surgery group.
The authors conclude that surgical revascularization
should be the benchmark for cost-effective treatment of
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severe aortoiliac occlusive disease. This claim is supported
by comparison of the mean total hospital cost ($10,585
for graft versus $9,161 for stent per limb affected). First, as
one of the experts in the discussion panel noted, the cost
of surgery is probably underestimated. Second, the
authors reported cost per limb affected rather than per
patient treated. Eighty-seven percent of the patients in the
surgery group and only 15% of the patients in the stent
group who underwent treatment had bilateral disease.
This nonrandomized assignment of patients with bilateral
disease favoring surgery adversely impacts on the cost for
the stent group. If more patients with bilateral disease had
stent deployment rather than surgery, the cost for the
stent group would be markedly reduced. By the current
assignment of most patients with bilateral disease to the
surgery group, the authors essentially reduced the cost of
surgery by 50%. It would be important to know the num-
ber of stents used per case because this information would
have an impact on the cost. For example, instead of using
two stents to treat a long lesion, one long stent would
lower the cost of the procedure.
Furthermore, I disagree with the statement that the
cost of the operating room time and the longer hospital-
ization (10 days for surgery versus 2 days for stenting) for
the surgery group did not impact on the total hospital
cost. The authors failed to include in the cost of surgery
the anesthesiologist's fees, the consultant's fees (to man-
age the severe complications in the surgery group), and
the costs associated with the preoperative workup and
evaluation before surgery, which are not required for stent
deployment.
Interventional radiologists at my institution place
stents for severe aortoiliac disease on an outpatient/ambu-
latory basis. Patients arrive in the morning for their stent
procedure and normally leave the hospital by late after-
noon on the same day. Rarely do these patients stay
overnight, unless a complication, which is rare, has
occurred. In this case, they are admitted overnight for
observation. The length of hospitalization for the stent
group in the article is higher than in my institution. In
summary, the reader should be made aware of the inher-
ent flaws in this article. A randomized, prospective study
should be undertaken before conclusions, which impact
on the decision of surgery versus stent deployment for the
treatment of severe aortoiliac disease, can be made.
Wen Y. Wang, MD
Vascular and Interventional Radiology Section
Department of Radiology




We appreciate the opportunity to respond to Dr
Wang's comments concerning our manuscript.! He con-
tends that there are significant flaws in our data presenta-
tion and raises some issues that require rebuttal, even
JOURNAL OF VASCULAR SURGERY
February 1999
though they were clearly stated in the manuscript. We can
assure Dr Wang that our data are truly representative of a
carefully studied group of patients with severe aortoiliac
occlusive disease, and we offer the following point-by-
point responses.
1. Our expert interventional radiology colleagues
were not included in the author list because they
did not assist in writing the manuscript nor were
they involved with the data collection for the pri-
mary study focus, which was cost. Previous publi-
cations from our institution concerning other
aspects of aortoiliac occlusive disease clearly give
deserved credit to these skilled individuals.2-4
Editors have taught us all to be increasingly cau-
tious in listing coauthors.
2. All the patients in this series were potential candi-
dates for operative intervention. This is in contrast
to other studies that have compared angioplasty
candidates with surgical patients.5,6 Our patients
with more severe disease allow the comparison of
the two therapies where they are currently compet-
ing with each other. In our practice, the treatment
for a category I iliac artery lesion is angioplasty with
or without stent deployment. Therefore, as was
clearly stated in the manuscript, these are nonsurgi-
cal cases. They could not be included when only
disease categories II to IV were studied. Also, as dis-
played in the manuscript, there was no selection
bias (any significant difference) between the two
groups.
3. Regarding a potential patency bias as a result of
group differences in infrainguinal occlusive disease,
this factor was not significant according to univari-
ate analysis. Therefore, Dr Wang's gross estimate
without statistical considerations is in error.
4. To answer another question, one stent was
deployed in 45 cases (57%), 2 in 25 cases (31.6%),
3 in 7 cases (8.9%), and 4 in 2 cases (2.5%).
5. The matter of cost analysis is more complex, con-
sisting of a number of items. First is the inclusion
of the anesthesia. Professional medicare reimburse-
ment for a 3-hour aortobifemoral (or aortobi-iliac)
bypass grafting procedure surprisingly did not
result in a statistically significant increase in mean
total cost of surgery ($10,830 versus $9161, P =
.172) and would not have changed our basic con-
clusions. However, we agree that tabulation of all
costs is more appropriate. We also would have liked
to include the cost of secondary procedures, but
unfortunately including the cost of failed proce-
dures (there were more stem failures) would have
been too complicated. We originally tried to
include preoperative costs, but this too was com-
plex because some patients referred to the clinic
had excellent arteriograms in hand and others had
to have better images before a treatment could be
selected. We were as surprised as Dr Wang was that
operating room time and length of stay data did
